Biocartis Strengthens Management Team with General Counsel Life Sciences and Biotechnology

Lausanne, Switzerland And Mechelen, Belgium (ots/PRNewswire) -

Biocartis, a molecular diagnostics company developing and
commercializing innovative, high quality, easy to use platforms and
clinically relevant oncology assays, announced today that Inge
Basteleurs has joined the company as General Counsel. Inge will be a
member of Biocartis' Executive Committee and a director of Biocartis
NV.

Inge Basteleurs brings to Biocartis an impressive track record
from a 17-year career as a senior international executive within the
biotechnology and pharmaceutical industries.

She joins Biocartis from UCB NV, where she was Vice President
Legal and Secretary General to the Board. Since 2006, Inge has held
various functions at UCB NV and was ultimately appointed Vice
President Legal, responsible for managing the company's business
development, research and international markets' legal department. In
this capacity, she was instrumental in completing several major
financing transactions, bond issuances, M&A and licensing deals,
totaling over 5.6bn Euro. Prior to joining UCB, Inge worked 7 seven
years at Bayer BioScience NV, where her role included global legal
responsibility for and membership of the management committee of
several of Bayer BioScience's business areas, including commercial
transactions, M&A, intellectual property licensing and government
affairs. Inge started her career as an M&A/finance solicitor at
Linklaters (De Bandt).

Inge received her Master in Law from KULeuven (Belgium), her LL.M
from University College London (UK) and her additional degree in
Managerial Economics from KULeuven.

"Inge brings to Biocartis a wealth of experience and a global
perspective on a broad range of legal matters in the life sciences
industry, together with her drive and fun personality which are
consistent with Biocartis' culture and values. She will support
Biocartis' transition to a global commercial enterprise. We are all
excited for her contribution," commented Greg Parekh, Chief Executive
Officer of Biocartis.

Commenting on her new role, Inge said: "Biocartis has all the
potential to become a global leader in the transformation from
traditional medicine toward personalized medicine and point of care
diagnostics. I am delighted to be joining Biocartis, its strong
Executive team and its consortium partners, at this exciting time, to
help guide the launch of its highly innovative molecular diagnostics
systems."

http://www.biocartis.com

ots Originaltext: Biocartis
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Contact: Greg Parekh, CEO , Tel: +41-21-694-04-30,
nhutsebaut@biocartis.com